Literature DB >> 28242263

Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness.

Randi Melissa Schuster1, Madeleine Fontaine2, Emily Nip2, Haiyue Zhang3, Ailish Hanly4, A Eden Evins2.   

Abstract

Young adults with psychiatric illnesses are more likely to use cannabis and experience problems from use. It is not known whether those with a lifetime psychiatric illness experience a prolonged cannabis withdrawal syndrome with abstinence. Participants were fifty young adults, aged 18-25, recruited from the Boston-area in 2015-2016, who used cannabis at least weekly, completed the Structured Clinical Interview for DSM-IV to identify Axis I psychiatric diagnoses (PD+ vs PD-), and attained cannabis abstinence with a four-week contingency management protocol. Withdrawal symptom severity was assessed at baseline and at four weekly abstinent visits using the Cannabis Withdrawal Scale. Cannabis dependence, age of initiation, and rate of abstinence were similar in PD+ and PD- groups. There was a diagnostic group by abstinent week interaction, suggesting a difference in time course for resolution of withdrawal symptoms by group, F(4,46)=3.8, p=0.009, controlling for sex, baseline depressive and anxiety symptoms, and frequency of cannabis use in the prior 90days. In post hoc analyses, there was a difference in time-course of cannabis withdrawal. PD- had significantly reduced withdrawal symptom severity in abstinent week one [t(46)=-2.2, p=0.03], while PD+ did not report improved withdrawal symptoms until the second abstinent week [t(46)=-4.1, p=0.0002]. Cannabis withdrawal symptoms improved over four weeks in young people with and without a lifetime psychiatric diagnosis. However, those with a psychiatric illness reported one week delayed improvement in withdrawal symptom severity. Longer duration of cannabis withdrawal may be a risk factor for cannabis dependence and difficulty quitting.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abstinence; Anxiety; Cannabis; Cannabis withdrawal syndrome; Depression; Marijuana; Mental health

Mesh:

Year:  2017        PMID: 28242263      PMCID: PMC5572754          DOI: 10.1016/j.ypmed.2017.02.019

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  50 in total

1.  Cannabis use and expression of mania in the general population.

Authors:  Cécile Henquet; Lydia Krabbendam; Ron de Graaf; Margreet ten Have; Jim van Os
Journal:  J Affect Disord       Date:  2006-06-21       Impact factor: 4.839

2.  Prospective evaluation of the effects of anxiety sensitivity and state anxiety in predicting acute nicotine withdrawal symptoms during smoking cessation.

Authors:  Kirsten A Johnson; Sherry Stewart; David Rosenfield; Dan Steeves; Michael J Zvolensky
Journal:  Psychol Addict Behav       Date:  2011-06-06

Review 3.  Endocannabinoid system dysfunction in mood and related disorders.

Authors:  C H Ashton; P B Moore
Journal:  Acta Psychiatr Scand       Date:  2011-03-09       Impact factor: 6.392

4.  Cannabis Withdrawal, Posttreatment Abstinence, and Days to First Cannabis Use Among Emerging Adults in Substance Use Treatment: A Prospective Study.

Authors:  Jordan P Davis; Douglas C Smith; Jason W Morphew; Xinrong Lei; Saijun Zhang
Journal:  J Drug Issues       Date:  2016-01

5.  Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence.

Authors:  Julia D Buckner; Norman B Schmidt; Alan R Lang; Jason W Small; Robert C Schlauch; Peter M Lewinsohn
Journal:  J Psychiatr Res       Date:  2007-02-23       Impact factor: 4.791

6.  Testing a tripartite model: I. Evaluating the convergent and discriminant validity of anxiety and depression symptom scales.

Authors:  D Watson; K Weber; J S Assenheimer; L A Clark; M E Strauss; R A McCormick
Journal:  J Abnorm Psychol       Date:  1995-02

7.  Anxiety as a predictor of age at first use of substances and progression to substance use problems among boys.

Authors:  Naomi R Marmorstein; Helene Raskin White; Rolf Loeber; Magda Stouthamer-Loeber
Journal:  J Abnorm Child Psychol       Date:  2010-02

8.  Excessive cannabis use is associated with earlier age at onset in bipolar disorder.

Authors:  Trine V Lagerberg; Kjetil Sundet; Sofie R Aminoff; Akiah O Berg; Petter A Ringen; Ole A Andreassen; Ingrid Melle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-01-26       Impact factor: 5.270

9.  Effects of endocannabinoid system modulation on cognitive and emotional behavior.

Authors:  Claudio Zanettini; Leigh V Panlilio; Mano Alicki; Steven R Goldberg; József Haller; Sevil Yasar
Journal:  Front Behav Neurosci       Date:  2011-09-13       Impact factor: 3.558

10.  Associations of cannabis and cigarette use with depression and anxiety at age 18: findings from the Avon Longitudinal Study of Parents and Children.

Authors:  Suzanne H Gage; Matthew Hickman; Jon Heron; Marcus R Munafò; Glyn Lewis; John Macleod; Stanley Zammit
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

View more
  5 in total

1.  DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults.

Authors:  Ofir Livne; Dvora Shmulewitz; Shaul Lev-Ran; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2018-10-22       Impact factor: 4.492

2.  Editorial for the special issue on behavior change, health, and health disparities 2017.

Authors:  Stephen T Higgins
Journal:  Prev Med       Date:  2017-10-29       Impact factor: 4.018

3.  Cannabis use, problem-gambling severity, and psychiatric disorders: Data from the National Epidemiological Survey on Alcohol and Related Conditions.

Authors:  Christopher J Hammond; Steven D Shirk; Dawn W Foster; Nicolas B Potenza; Shane W Kraus; Linda C Mayes; Rani A Hoff; Marc N Potenza
Journal:  Psychol Addict Behav       Date:  2019-06-27

4.  Progression of cannabis withdrawal symptoms in people using medical cannabis for chronic pain.

Authors:  Lara N Coughlin; Mark A Ilgen; Mary Jannausch; Maureen A Walton; Kipling M Bohnert
Journal:  Addiction       Date:  2021-01-06       Impact factor: 7.256

5.  Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

Authors:  Benedikt Bernd Claus; Michael Specka; Heath McAnally; Norbert Scherbaum; Fabrizio Schifano; Udo Bonnet
Journal:  Front Psychiatry       Date:  2020-12-03       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.